Prognostic impact of statin use in patients with heart failure and preserved ejection fraction

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• The role of statins in heart failure (HF) management, particularly in patients with preserved ejection fraction (HFpEF), requires further investigation.
• Statins are widely used cholesterol-lowering drugs with potential pleiotropic effects beyond lipid modification.

Purpose of the Study:

• To evaluate the effectiveness of statin therapy on mortality rates in patients diagnosed with heart failure with preserved ejection fraction (HFpEF).
• To compare the impact of statin use on mortality between HFpEF and heart failure with reduced ejection fraction (HFrEF) patient cohorts.

Main Methods:

• Analysis of 4,544 consecutive HF patients from the CHART-2 registry (2006-2010).
• Stratification into HFpEF (EF ≥50%) and HFrEF (EF <50%) groups, with median follow-up of 3.4 years.
• Statistical analyses including adjusted hazard ratios, propensity score matching, and inverse probability of treatment weighting to assess statin effectiveness.

Main Results:

• In HFpEF patients, statin use was associated with significantly lower 3-year mortality (8.7% vs. 14.5%, HR 0.74).
• Propensity score matching and inverse probability of treatment weighting confirmed reduced all-cause death (HR 0.71) and noncardiovascular death (HR 0.53) with statin use in HFpEF.
• Specific reductions in sudden death (HR 0.59) and infection-related death (HR 0.53) were noted in HFpEF patients on statins.
• No significant association between statin use and mortality was found in the HFrEF cohort (HR 0.87).

Conclusions:

• Statin therapy is linked to improved survival rates in patients with HFpEF.
• The mortality benefits in HFpEF appear primarily driven by reductions in sudden cardiac death and noncardiovascular mortality.
• Statins did not demonstrate a significant survival benefit in patients with HFrEF in this study.